Comorbidities Drive Outcomes for Both Malignancy-Associated and Non–Malignancy-Associated Hemophagocytic Syndrome

Conclusion Malignancy-associated HPS, CCI ≥ 2, age > 50 years, and Medicare patients were associated with a worse in-hospital mortality. In multivariate analysis, greater comorbidity burden appeared to be the single most important predictor of mortality. This suggests that outcomes for adults with HPS are predicated by the extent of organ dysfunction at diagnosis. Micro-Abstract Secondary hemophagocytic syndrome (SHPS) is a rare syndrome that develops in the context of infection, autoimmune disease, or underlying malignancy, resulting in unregulated activation of the immune system. Through a retrospective analysis of a large inpatient national database and the Charlson comorbidity index (CCI), we identified novel predictors of mortality among 276 hospitalizations in adults with SHPS.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research